NCT06025344View on ClinicalTrials.gov

A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

October 15, 2024

Conditions
Relative Bioavailability
Interventions
DRUG

PanCytoVir™ 100 mg/mL oral suspension

Single oral dose of 1000 mg (100 mg/mL) under fasted conditions

DRUG

Probenecid 500 mg

Single oral dose of 1000 mg under fasted conditions

Trial Locations (1)

Unknown

Vayam Research Solutions Limited, Gujrāt

All Listed Sponsors
lead

TrippBio, Inc.

INDUSTRY

NCT06025344 - A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml) | Biotech Hunter | Biotech Hunter